Multiple sales of MassARRAY® systems have taken place in China, according to Sequenom. The company’s new customers include the Beijing Genomics Institute (BGI), which plans to initially use the system for its advanced research in viral genetics and later for human genetic projects, and CapitalBio, a company that plans expand into the fine mapping market from whole genome association studies.
“We chose Sequenom’s MassARRAY technology because it features a unique combination of throughput, accuracy, sensitivity, reproducibility, and cost efficiency,” explains Wang Wei, BGI’s director of viral genotyping.
“It is particularly suitable for the high-volume viral genotyping project and other population-screening projects we plan to undertake in the near future.”
